Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Santini

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Leukemia Research|January 24, 2007
A selective activity of DNMTi decitabine on AML1ETO positive cells?Valeria Santini
Seminars in Hematology|September 26, 2015
Anemia as the Main Manifestation of Myelodysplastic SyndromesValeria Santini
Blood|December 15, 2018
How I treat MDS after hypomethylating agent failureValeria Santini
Leukemia Research|December 14, 2011
The quest for the perfect MDS scoring systemValeria Santini
The Oncologist|September 21, 2011
Clinical use of erythropoietic stimulating agents in myelodysplastic syndromesValeria Santini
Expert Review of Hematology|November 19, 2010
Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromesValeria Santini
Hematology. American Society of Hematology. Education Program|December 4, 2016
Treatment of low-risk myelodysplastic syndromesValeria Santini
Seminars in Hematology|October 20, 2012
Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietinsValeria Santini
Hematology. American Society of Hematology. Education Program|December 13, 2012
Novel therapeutic strategies: hypomethylating agents and beyondValeria Santini
Leukemia Research|March 10, 2009
Is survival enough for myelodysplastic syndromes?Valeria Santini
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Leukemia Research|January 24, 2007
A selective activity of DNMTi decitabine on AML1ETO positive cells?Valeria Santini
Seminars in Hematology|September 26, 2015
Anemia as the Main Manifestation of Myelodysplastic SyndromesValeria Santini
Blood|December 15, 2018
How I treat MDS after hypomethylating agent failureValeria Santini
Leukemia Research|December 14, 2011
The quest for the perfect MDS scoring systemValeria Santini
The Oncologist|September 21, 2011
Clinical use of erythropoietic stimulating agents in myelodysplastic syndromesValeria Santini
Expert Review of Hematology|November 19, 2010
Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromesValeria Santini
Hematology. American Society of Hematology. Education Program|December 4, 2016
Treatment of low-risk myelodysplastic syndromesValeria Santini
Seminars in Hematology|October 20, 2012
Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietinsValeria Santini
Hematology. American Society of Hematology. Education Program|December 13, 2012
Novel therapeutic strategies: hypomethylating agents and beyondValeria Santini
Leukemia Research|March 10, 2009
Is survival enough for myelodysplastic syndromes?Valeria Santini
Pageof 23